YOU ARE HERE:
Triomune approved for PEPFAR use
The US Food and Drug Administration announced last week that it has granted tentative approbal to a fixed dose triple combination of the antiretroviral drugs nevirapine, stavudine and lamivudine. The product is marketed by Cipla as Triomune, and will now be available for purchase by United States PEPFAR-funded treatment programmes worldwide (PEPFAR is the President's Emergency Plan for AIDS Relief, founded in 2003 to deliver antiretroviral treatment and HIV prevention in developing countries).
Triomune is already one of the most widely used generic antiretroviral products in developing countries because it combines three drugs recommended for first-line therapy by the World Health Organization into one tablet.
According to the Boston Globe, generic antiretroviral drugs now account for almost 70% of PEPFAR-funded HIV treatment in Haiti, Nigeria and Zambia, three of the 15 countries targeted by the programme.
Triomune is already one of the most widely used generic antiretroviral products in developing countries because it combines three drugs recommended for first-line therapy by the World Health Organization into one tablet.
According to the Boston Globe, generic antiretroviral drugs now account for almost 70% of PEPFAR-funded HIV treatment in Haiti, Nigeria and Zambia, three of the 15 countries targeted by the programme.
aidsmap resources
Africa news
- People with HIV providing high quality treatment support in community
- Nurse prescribing of ARVs: evidence of success in Rwanda and Lesotho
- Cost-effective ways to reduce loss to follow-up in ART programmes identified
New drugs news
- New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
- FDA committee recommends approval of maraviroc for first-line treatment in US
- Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
Treatment access news
feedback
Give us your views on our work